HC Wainwright Reaffirms “Neutral” Rating for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating restated by HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

CytomX Therapeutics Stock Performance

CTMX stock opened at $1.04 on Monday. The stock has a market cap of $81.24 million, a PE ratio of 6.12 and a beta of 1.06. CytomX Therapeutics has a 12 month low of $0.98 and a 12 month high of $5.85. The company has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.47.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The business had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. CytomX Therapeutics had a negative return on equity of 37.72% and a net margin of 10.96%. During the same quarter last year, the firm posted $0.04 earnings per share. Sell-side analysts forecast that CytomX Therapeutics will post -0.29 EPS for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new position in CytomX Therapeutics during the first quarter valued at approximately $57,000. US Bancorp DE purchased a new stake in shares of CytomX Therapeutics during the 3rd quarter worth $40,000. Susquehanna Fundamental Investments LLC purchased a new position in CytomX Therapeutics in the first quarter valued at about $124,000. XTX Topco Ltd raised its holdings in CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares in the last quarter. Finally, Forefront Analytics LLC lifted its position in shares of CytomX Therapeutics by 206.7% during the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.